Reactive oxygen species modulator 1 (Romo1) predicts poor outcomes in advanced non-small cell lung cancer patients treated with platinum-based chemotherapy

Seung Hyeun Lee, Sue In Choi, Ji Sung Lee, Chul Hwan Kim, Won Jai Jung, Eun Joo Lee, Kyung-Hoon Min, Gyu Young Hur, Seung Heon Lee, Sung Yong Lee, Je Hyeong Kim, Sang Yeub Lee, Chol Shin, Jae Jeong Shim, Kyung Ho Kang, Kwang Ho In

Research output: Contribution to journalArticle

4 Citations (Scopus)

Abstract

Purpose Reactive oxygen species modulator 1 (Romo1) is a key mediator of intracellular reactive oxygen species production. However, examination of the clinical usefulness of Romo1 in cancers has been limited. We evaluated the association of Romo1 expression with clinical outcomes in advanced non-small cell lung cancer (NSCLC) patients treated with platinumbased chemotherapy. Materials and Methods Romo1 expression in tumor tissue was examined by immunohistochemistry and evaluated by histological score. Survival analyses were performed according to Romo1 expression and the association between Romo1 expression and clinical parameters was evaluated. Results A total of 88 tumor specimens were analyzed. Significantly shorter median progression-free survival (PFS) was observed in the high Romo1 group compared with the low Romo1 group (4.5 months vs. 9.8 months, p < 0.001), and the median overall survival (OS) of the high Romo1 group was also significantly shorter than that of the low Romo1 group (8.4 months vs. 15.5 months, p < 0.001). Results of multivariate analyses showed significant association of high Romo1 expression with both poor PFS (hazard ratio [HR], 2.75; 95% confidence interval [CI], 1.71 to 4.44) and poor OS (HR, 3.99; 95% CI, 2.36 to 6.74). Results of the subgroup analysis showed a similar association regardless of tumor histology. Romo1 expression showed no association with any clinical parameter including age, sex, smoking status, stage, differentiation, or tumor histology. Conclusion Romo1 overexpression was associated with poor response to treatment and shorter survival in advanced NSCLC patients treated with platinum-based chemotherapy. Romo1 could be a potential adverse predictive marker in this setting.

Original languageEnglish
Pages (from-to)141-149
Number of pages9
JournalCancer Research and Treatment
Volume49
Issue number1
DOIs
Publication statusPublished - 2017

Fingerprint

Platinum
Non-Small Cell Lung Carcinoma
Reactive Oxygen Species
Drug Therapy
Neoplasms
Disease-Free Survival
Survival
Histology
Confidence Intervals
Survival Analysis
Multivariate Analysis

Keywords

  • Biomarkers
  • Drug therapy
  • Lung neoplasms
  • Platinum
  • Prognosis
  • Reactive oxygen species

ASJC Scopus subject areas

  • Oncology
  • Cancer Research

Cite this

@article{e534127176014f568147c89899845be3,
title = "Reactive oxygen species modulator 1 (Romo1) predicts poor outcomes in advanced non-small cell lung cancer patients treated with platinum-based chemotherapy",
abstract = "Purpose Reactive oxygen species modulator 1 (Romo1) is a key mediator of intracellular reactive oxygen species production. However, examination of the clinical usefulness of Romo1 in cancers has been limited. We evaluated the association of Romo1 expression with clinical outcomes in advanced non-small cell lung cancer (NSCLC) patients treated with platinumbased chemotherapy. Materials and Methods Romo1 expression in tumor tissue was examined by immunohistochemistry and evaluated by histological score. Survival analyses were performed according to Romo1 expression and the association between Romo1 expression and clinical parameters was evaluated. Results A total of 88 tumor specimens were analyzed. Significantly shorter median progression-free survival (PFS) was observed in the high Romo1 group compared with the low Romo1 group (4.5 months vs. 9.8 months, p < 0.001), and the median overall survival (OS) of the high Romo1 group was also significantly shorter than that of the low Romo1 group (8.4 months vs. 15.5 months, p < 0.001). Results of multivariate analyses showed significant association of high Romo1 expression with both poor PFS (hazard ratio [HR], 2.75; 95{\%} confidence interval [CI], 1.71 to 4.44) and poor OS (HR, 3.99; 95{\%} CI, 2.36 to 6.74). Results of the subgroup analysis showed a similar association regardless of tumor histology. Romo1 expression showed no association with any clinical parameter including age, sex, smoking status, stage, differentiation, or tumor histology. Conclusion Romo1 overexpression was associated with poor response to treatment and shorter survival in advanced NSCLC patients treated with platinum-based chemotherapy. Romo1 could be a potential adverse predictive marker in this setting.",
keywords = "Biomarkers, Drug therapy, Lung neoplasms, Platinum, Prognosis, Reactive oxygen species",
author = "Lee, {Seung Hyeun} and Choi, {Sue In} and Lee, {Ji Sung} and Kim, {Chul Hwan} and Jung, {Won Jai} and Lee, {Eun Joo} and Kyung-Hoon Min and Hur, {Gyu Young} and Lee, {Seung Heon} and Lee, {Sung Yong} and Kim, {Je Hyeong} and Lee, {Sang Yeub} and Chol Shin and Shim, {Jae Jeong} and Kang, {Kyung Ho} and In, {Kwang Ho}",
year = "2017",
doi = "10.4143/crt.2016.133",
language = "English",
volume = "49",
pages = "141--149",
journal = "Cancer Research and Treatment",
issn = "1598-2998",
publisher = "Korean Society for Thoracic and Cardiovascular Surgery",
number = "1",

}

TY - JOUR

T1 - Reactive oxygen species modulator 1 (Romo1) predicts poor outcomes in advanced non-small cell lung cancer patients treated with platinum-based chemotherapy

AU - Lee, Seung Hyeun

AU - Choi, Sue In

AU - Lee, Ji Sung

AU - Kim, Chul Hwan

AU - Jung, Won Jai

AU - Lee, Eun Joo

AU - Min, Kyung-Hoon

AU - Hur, Gyu Young

AU - Lee, Seung Heon

AU - Lee, Sung Yong

AU - Kim, Je Hyeong

AU - Lee, Sang Yeub

AU - Shin, Chol

AU - Shim, Jae Jeong

AU - Kang, Kyung Ho

AU - In, Kwang Ho

PY - 2017

Y1 - 2017

N2 - Purpose Reactive oxygen species modulator 1 (Romo1) is a key mediator of intracellular reactive oxygen species production. However, examination of the clinical usefulness of Romo1 in cancers has been limited. We evaluated the association of Romo1 expression with clinical outcomes in advanced non-small cell lung cancer (NSCLC) patients treated with platinumbased chemotherapy. Materials and Methods Romo1 expression in tumor tissue was examined by immunohistochemistry and evaluated by histological score. Survival analyses were performed according to Romo1 expression and the association between Romo1 expression and clinical parameters was evaluated. Results A total of 88 tumor specimens were analyzed. Significantly shorter median progression-free survival (PFS) was observed in the high Romo1 group compared with the low Romo1 group (4.5 months vs. 9.8 months, p < 0.001), and the median overall survival (OS) of the high Romo1 group was also significantly shorter than that of the low Romo1 group (8.4 months vs. 15.5 months, p < 0.001). Results of multivariate analyses showed significant association of high Romo1 expression with both poor PFS (hazard ratio [HR], 2.75; 95% confidence interval [CI], 1.71 to 4.44) and poor OS (HR, 3.99; 95% CI, 2.36 to 6.74). Results of the subgroup analysis showed a similar association regardless of tumor histology. Romo1 expression showed no association with any clinical parameter including age, sex, smoking status, stage, differentiation, or tumor histology. Conclusion Romo1 overexpression was associated with poor response to treatment and shorter survival in advanced NSCLC patients treated with platinum-based chemotherapy. Romo1 could be a potential adverse predictive marker in this setting.

AB - Purpose Reactive oxygen species modulator 1 (Romo1) is a key mediator of intracellular reactive oxygen species production. However, examination of the clinical usefulness of Romo1 in cancers has been limited. We evaluated the association of Romo1 expression with clinical outcomes in advanced non-small cell lung cancer (NSCLC) patients treated with platinumbased chemotherapy. Materials and Methods Romo1 expression in tumor tissue was examined by immunohistochemistry and evaluated by histological score. Survival analyses were performed according to Romo1 expression and the association between Romo1 expression and clinical parameters was evaluated. Results A total of 88 tumor specimens were analyzed. Significantly shorter median progression-free survival (PFS) was observed in the high Romo1 group compared with the low Romo1 group (4.5 months vs. 9.8 months, p < 0.001), and the median overall survival (OS) of the high Romo1 group was also significantly shorter than that of the low Romo1 group (8.4 months vs. 15.5 months, p < 0.001). Results of multivariate analyses showed significant association of high Romo1 expression with both poor PFS (hazard ratio [HR], 2.75; 95% confidence interval [CI], 1.71 to 4.44) and poor OS (HR, 3.99; 95% CI, 2.36 to 6.74). Results of the subgroup analysis showed a similar association regardless of tumor histology. Romo1 expression showed no association with any clinical parameter including age, sex, smoking status, stage, differentiation, or tumor histology. Conclusion Romo1 overexpression was associated with poor response to treatment and shorter survival in advanced NSCLC patients treated with platinum-based chemotherapy. Romo1 could be a potential adverse predictive marker in this setting.

KW - Biomarkers

KW - Drug therapy

KW - Lung neoplasms

KW - Platinum

KW - Prognosis

KW - Reactive oxygen species

UR - http://www.scopus.com/inward/record.url?scp=85010424648&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85010424648&partnerID=8YFLogxK

U2 - 10.4143/crt.2016.133

DO - 10.4143/crt.2016.133

M3 - Article

C2 - 27188201

AN - SCOPUS:85010424648

VL - 49

SP - 141

EP - 149

JO - Cancer Research and Treatment

JF - Cancer Research and Treatment

SN - 1598-2998

IS - 1

ER -